Synapse - Jae Park

Search Within

Jae Hong Park

Results (378)

A phase I first-in-human clinical trial of CD19-targeted 19-28z/4-1BBL "armored" CAR T cells in patients with relapsed or refractory NHL and CLL including Richter's transformation

Meeting Abstract

Park, J. H.; Palomba, M. L.; Batlevi, C. L.; Riviere, I.; Wang, X.; Senechal, B.; Furman, R. R.; Bernal, Y.; Hall, M.; Pineda, J.; more...
Blood (2018)

Fulltext@MSK | Save

Clinical responses and pharmacokinetics of MCARH171, a human-derived BCMA targeted CAR T cell therapy in relapsed/refractory multiple myeloma: Final results of a phase I clinical trial

Meeting Abstract

Mailankody, S.; Ghosh, A.; Staehr, M.; Purdon, T. J.; Roshal, M.; Halton, E.; Diamonte, C.; Pineda, J.; Anant, P.; Bernal, Y.; more...
Blood (2018)

Fulltext@MSK | Save

Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia

Meeting Abstract

King, A. C.; Pappacena, J.; Tallman, M. S.; Park, J. H.; Geyer, M. B.
Blood (2018)

Fulltext@MSK | Save

Hypofibrinogenemia and disseminated intravascular coagulation rarely complicate treatment-naive acute lymphoblastic leukemia

Meeting Abstract

Gaulin, C.; Chan, A.; Geyer, M. B.; Park, J. H.; Mantha, S.; Tallman, M. S.
Blood (2018)

Fulltext@MSK | Save

Ruxolitinib in combination with dasatinib and dexamethasone is an active and well-tolerated chemotherapy-sparing oral induction regimen for adults with Philadelphia chromosome-positive ALL: Results of a phase I trial

Meeting Abstract

Geyer, M. B.; Burke, P. W.; King, A. C.; Mauro, M. J.; Tallman, M. S.; Levine, R. L.; Sherr, C. J.; Douer, D.; Park, J. H.
Blood (2018)

Fulltext@MSK | Save

Prediction of CAR T-related toxicities in R/R DLBCL patients treated with axicabtagene ciloleucel using point of care cytokine measurements

Meeting Abstract

Faramand, R.; Kotani, H.; Morrissey, D.; Yu, B.; Locke, F. L.; Jain, M. D.; Chavez, J. C.; Wang, X.; Mishra, A.; Bachmeier, C. A.; more...
Blood (2018)

Fulltext@MSK | Save

A phase 2 study of actinium-225 ((225)Ac)-lintuzumab in older patients with untreated acute myeloid leukemia (AML) - Interim analysis of 1.5 µci/kg/dose

Meeting Abstract

Atallah, E. L.; Orozco, J. J.; Craig, M.; Levy, M. Y.; Finn, L. E.; Khan, S. S.; Perl, A. E.; Park, J. H.; Roboz, G. J.; Tse, W.; more...
Blood (2018)

Fulltext@MSK | Save

Results of SWOG 1318: A phase 2 trial of blinatumomab followed by POMP (prednisone, vincristine, methotrexate, 6-mercaptopurine) maintenance in elderly patients with newly diagnosed Philadelphia chromosome negative B-cell acute lymphoblastic leukemia

Meeting Abstract

Advani, A. S.; Moseley, A.; O'Dwyer, K. M.; Wood, B.; Fang, M.; Wieduwilt, M. J.; Aldoss, I.; Park, J. H.; Klisovic, R.; Baer, M. R.; more...
Blood (2018)

Fulltext@MSK | Save

Intestinal microbiota composition prior to CAR T cell infusion correlates with efficacy and toxicity

Meeting Abstract

Smith, M.; Littmann, E. R.; Slingerland, J. B.; Clurman, A.; Slingerland, A. E.; Taur, Y.; Schluter, J.; Park, J. H.; O'Cearbhaill, R.; Mailankody, S.; more...
Blood (2018)

Fulltext@MSK | Save

Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of MRD negativity in adults ages 18-60 with Philadelphia chromosome-negative acute lymphoblastic leukemia and lymphoblastic lymphoma

Meeting Abstract

Geyer, M. B.; Ritchie, E. K.; Rao, A. V.; Cazacu, M. I.; Vemuri, S.; Tallman, M. S.; Douer, D.; Park, J. H.
Blood (2018)

Fulltext@MSK | Save